2-[(4-氯苯基)甲基]环己烷-1-酮 | 2702-79-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[(4-氯苯基)甲基]环己烷-1-酮
• 英文名称: 2-(4-chloro-benzyl)-cyclohexanone
• 英文别名: 2-(4-Chlor-benzyl)-cyclohexanon；2-(4-chlorobenzyl)cyclohexanone；2-<4-Chlor-benzyl>-cyclohexanon；Cyclohexanone, 2-((4-chlorophenyl)methyl)-；2-[(4-chlorophenyl)methyl]cyclohexan-1-one
• CAS: 2702-79-6
• 化学式: C₁₃H₁₅ClO
• 分子量: 222.715
• InChiKey: UNJQQZUSORSFMS-UHFFFAOYSA-N

物化性质

• 熔点：
  139-141 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  130-132 °C(Press: 0.2 Torr)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  2-[(4-氯苯基)甲基]环己烷-1-酮 在 盐酸 、 正丁基锂 、 三乙胺 、 二异丙胺 作用下， 反应 4.75h， 生成 7-(4-Chloro-benzyl)-1-(4-fluoro-phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbaldehyde
  参考文献：
  名称：

  HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts

  摘要：

  Compounds comprising a series of 7-[2-(4-fluorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-3,5-dihydroxy-6-heptenoic acid sodium salts (18) were synthesized and tested for their ability to inhibit HMG-CoA reductase in a partially purified enzyme preparation and cholesterol biosynthesis from acetate in cultured HEP-G2 cells. Changing the size of the saturated ring of the tetrahydroindazole nucleus did not improve potency, but incorporation of substituents at the 7-position resulted in up to 1700-fold improvement in inhibitory potency. Structure-activity studies revealed that the most potent compounds possess a substituted benzyl group at the 7-position, with a preference for steric bulk at the para position of the benzene ring. The most potent enzyme inhibitor (18t, IC50 = 3.0 nM) is approximately 3-fold more potent than lovastatin sodium salt (2). The most potent cholesterol biosynthesis inhibitor in HEP-G2 cells (18q, IC50 = 0.078 muM) is slightly less potent than 2 (sodium salt). Molecular modeling studies suggested that, when compared to the parent compound (18b) lacking the appropriate 7-substituent, 18t overlaps better with 2 and literature inhibitors 5 and 6 in a hydrophobic binding region adjacent to the enzyme active site.

  DOI：

  10.1021/jm00075a024
• 作为产物：
  描述：

  (E)-2-(4-chloro-phenylmethylene)-cyclohexanol 以 正己烷 为溶剂， 生成 2-[(4-氯苯基)甲基]环己烷-1-酮
  参考文献：
  名称：

  取代基和溶剂极性对光化学[1,3]σ位移的影响。实验证据支持突发性事件的发生

  摘要：

  提供了有关在无环烯烃中突然极化的进一步实验证据。结果表明，分子内光化学[1,3] -OH的转变为1所生成的产物的产率仅取决于所用溶剂的极性。可以通过偶极溶剂分子的重新取向极化来稳定在辐射1时形成的两性离子中间体，从而很好地解释该结果。除此之外，发现在C 3 -C 9的末端碳原子处的烷基被取代。1中被苯基取代基形成的环外双键导致发生光化学[1,3] -H移位。取代基在环外双键上的这种指导作用可以在突然极化模型的基础上很好地解释。

  DOI：

  10.1016/s0040-4020(01)86197-4

文献信息

• 2-(Optionally-substituted)benzylperhydroazepines for analgesia and
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：US04221788A1

  公开（公告）日：1980-09-09

  Title compounds and their acid-addition salts are physiologically acceptable or are readily converted to physiologically-acceptable counterparts by established procedures. They are pharmacologically active on the central nervous system (CNS) and are thus useful, when administered to warm-blooded animals, to induce central stimulation, to increase vigilance and to promote normal and pathologically-inhibited drive. They are also useful as analgesics and as blood-pressure-reducing agents for warm-blooded animals. These compounds are prepared, e.g., by reducing an appropriate 2-benzylazacycloheptane and are compounded into normal dosage-form medicament compositions.

  标题化合物及其酸盐在生理上是可接受的，或者可以通过已建立的程序轻松转化为生理上可接受的对应物。它们在中枢神经系统（CNS）上具有药理活性，因此在给温血动物施用时，可用于诱导中枢兴奋，增加警觉性，并促进正常和病理性抑制驱动力。它们还可用作镇痛剂和温血动物的降压剂。这些化合物可以通过合适的2-苄基氮杂环庚烷还原等方法制备，并制成常规剂型的药物组合物。
• Process for preparation of azolylmethylcycloalkanol derivatives
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：US05466816A1

  公开（公告）日：1995-11-14

  A process for preparing a derivative of azolylmethylcycloalkanol of the following formula (I) comprising, providing a solid-liquid two-phase mixture of a cycloalkanone derivative of formula (II), an azole compound of formula (III), a metal oxide of formula (IV), and an organic solvent, and adding a sulfonium compound of formula (V) to said solid-liquid two-phase mixture under heating while stirring, ##STR1## wherein R.sup.1 and R.sup.2 individually represent a hydrogen atom or an alkyl group; X is a halogen atom, an alkyl group, a haloalkyl group, a phenyl group, a cyano group, or a nitro group; m is an integer of 0 to 5 (when m is 2 or larger, Xs may be either the same or different); n is an integer of 0 to 2; A represents a nitrogen atom or a group CH; M.sup.1 represents an alkali metal atom or an alkaline earth metal atom; M.sup.2 represents an alkaline earth metal atom, a zinc atom, or two alkali metal atoms; Y represents a halogen atom or a C.sub.1 -C.sub.4 alkoxysulfonyloxy group; and p denotes an integer of 0 or 1.

  一种制备以下结构式（I）的咪唑甲基环烷醇衍生物的方法，包括提供具有结构式（II）的环烷酮衍生物、具有结构式（III）的咪唑化合物、具有结构式（IV）的金属氧化物和有机溶剂的固液两相混合物，并在加热搅拌的情况下向所述固液两相混合物中加入具有结构式（V）的磺化物化合物， 其中R.sup.1和R.sup.2分别表示氢原子或烷基；X是卤素原子、烷基、卤代烷基、苯基、氰基或硝基；m为0至5的整数（当m为2或更大时，Xs可以是相同的或不同的）；n为0至2的整数；A表示氮原子或CH基团；M.sup.1表示碱金属原子或碱土金属原子；M.sup.2表示碱土金属原子、锌原子或两个碱金属原子；Y表示卤素原子或C.sub.1 -C.sub.4烷氧磺酰氧基团；p表示0或1的整数。
• Tetrahydroindazole, tetrahydrocyclopentapyrazole, and
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05387693A1

  公开（公告）日：1995-02-07

  Compounds of the general formula I: ##STR1## are disclosed as useful in the treatment or prevention of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis. Novel intermediate compounds used to make the compound of formula I are also disclosed.

  一般式I的化合物：##STR1## 被披露为在治疗或预防高胆固醇血症、高脂蛋白血症和动脉粥样硬化方面具有用途。还披露了用于制备一般式I化合物的新型中间体化合物。
• <i>β</i>-Arylation of oxime ethers using diaryliodonium salts through activation of inert C(sp)–H bonds using a palladium catalyst
  作者：Jing Peng、Chao Chen、Chanjuan Xi

  DOI：10.1039/c5sc03903g

  日期：——

  Palladium catalyzed selectiveβ-arylation of oxime ethers was realized using diaryliodonium salts as the key arylation reagents.

  钯催化的氧肟醚的选择性β-芳基化反应是利用二芳基碘盐作为关键的芳基化试剂实现的。
• Process for the preparation of azolylmethylcycloalkanol derivatives
  申请人：KUREHA CHEMICAL INDUSTRY CO., LTD.

  公开号：EP0655443A2

  公开（公告）日：1995-05-31

  A process for preparing a derivative of azolylmethylcycloalkanol of the following formula (I) comprising, providing a solid-liquid two-phase mixture of a cycloalkanone derivative of formula (II), an azole compound of formula (III), a metal oxide of formula (IV), and an organic solvent, and adding a sulfonium compound of formula (V) to said solid-liquid two-phase mixture under heating while stirring, wherein R¹ and R² individually represent a hydrogen atom or an alkyl group; X is a halogen atom, an alkyl group, a haloalkyl group, a phenyl group, a cyano group, or a nitro group; m is an integer of 0 to 5 (when m is 2 or larger, Xs may be either the same or different); n is an integer of 0 to 2; A represents a nitrogen atom or a group CH; M¹ represents an alkali metal atom or an alkaline earth metal atom; M² represents an alkaline earth metal atom, a zinc atom, or two alkali metal atoms; Y represents a halogen atom or a C₁-C₄ alkoxysulfonyloxy group; and p denotes an integer of 0 or 1.

  一种制备下式(I)的唑甲基环烷醇衍生物的工艺，包括：提供由式(II)的环烷酮衍生物、式(III)的唑化合物、式(IV)的金属氧化物和有机溶剂组成的固液两相混合物，并在加热搅拌下向所述固液两相混合物中加入式(V)的锍化合物、 其中 R¹ 和 R² 分别代表氢原子或烷基；X 是卤素原子、烷基、卤代烷基、苯基、氰基或硝基；m 是 0 至 5 的整数（当 m 为 2 或更大时，Xs 可以相同或不同）；n 是 0 至 2 的整数；A 代表氮原子或基团 CH；M¹ 代表碱金属原子或碱土金属原子；M² 代表碱土金属原子、锌原子或两个碱金属原子；Y 代表卤素原子或 C₁-C₄ 烷氧基磺酰氧基；p 表示 0 或 1 的整数。